Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: Examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 1, 2013, Pages 44-51

  Berrill, J W ^a   Green, J T ^a   Hood, K ^b   Campbell, A K ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ADULT; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CROHN DISEASE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ACTIVITY; ENTERITIS; FECES ANALYSIS; FEMALE; HARVEY BRADSHAW INDEX; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; SEX RATIO; SIMPLE CLINICAL COLITIS ACTIVITY INDEX; ULCERATIVE COLITIS;

ADULT; ANXIETY; CROSS-SECTIONAL STUDIES; DEPRESSION; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84878808685     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12335     Document Type: Article

References (43)

1. Longstreth GF, Thompson WG, Chey WD, et al,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Halder SL, Locke GR 3rd, Talley NJ, et al,. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 233-42.
3. Lovell RM, Ford AC,. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 991-1000.
4. Henningsen P, Zimmermann T, Sattel H,. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-33.
5. Ford AC, Talley NJ, Schoenfeld PS, et al,. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
6. Whitehead WE, Palsson O, Jones KR,. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-56.
7. Spiller R, Aziz Q, Creed F, et al,. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
8. Halpin SJ, Ford AC,. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-82.
9. Drossman DA, Camilleri M, Mayer EA, et al,. AGA technical review on irritable bowel syndrome. Gastroenterology [Review] 2002; 123: 2108-31.
10. Barratt HS, Kalantzis C, Polymeros D, et al,. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment Pharmacol Ther 2005; 21: 141-7.
11. Long MD, Drossman DA,. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy. Am J Gastroenterol 2010; 105: 1796-8.
12. Lahiff C, Safaie P, Awais A, et al,. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 786-94.
13. Akbar A, Yiangou Y, Facer P, et al,. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010; 59: 767-74.
14. Keohane J, O'Mahony C, O'Mahony L, et al,. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 9-94.
15. Collins SM,. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111: 1683-99.
16. Farrokhyar F, Marshall JK, Easterbrook B, et al,. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006; 12: 38-46.
17. Stange EF, Travis SP, Vermeire S, et al,. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl. 1): i1-15.
18. Van Assche G, Dignass A, Panes J, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
19. Silverberg MS, Satsangi J, Ahmad T, et al,. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5-36.
20. Walmsley RS, Ayres RC, Pounder RE, et al,. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
21. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
22. Zigmoid AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
23. Mikocka-Walus AA, Turnbull DA, Andrews JM, et al,. The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 475-83.
24. Isgar B, Harman M, Kaye MD, et al,. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-2.
25. Minderhoud IM, Oldenburg B, Wismeijer JA, et al,. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-74.
26. Piche T, Ducrotte P, Sabate JM, et al,. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 626-e174.
27. Simren M, Axelsson J, Gillberg R, et al,. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-96.
28. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al,. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis 2007; 13: 225-34.
29. Graff LA, Walker JR, Bernstein CN,. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009; 15: 1105-18.
30. Langhorst J, Elsenbruch S, Koelzer J, et al,. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-9.
31. Schoepfer AM, Beglinger C, Straumann A, et al,. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.
32. Sipponen T, Karkkainen P, Savilahti E, et al,. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-9.
33. Roseth AG, Aadland E, Jahnsen J, et al,. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-80.
34. D'Haens G, Ferrante M, Vermeire S, et al,. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-24.
35. Landis JR, Koch GG,. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
36. Sipponen T, Savilahti E, Kolho KL, et al,. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-6.
37. Camilleri M,. Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. Gut 2011; 60: 425-8.
38. Eadala P, Matthews SB, Waud JP, et al,. Association of lactose sensitivity with inflammatory bowel disease-demonstrated by analysis of genetic polymorphism, breath gases and symptoms. Aliment Pharmacol Ther 2011; 34: 735-46.
39. Ford AC, Talley NJ, Spiegel BM, et al,. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
40. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al,. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006; 2: 24.
41. Timmer A, Preiss JC, Motschall E, et al,. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011; (2): CD006913.
42. Gearry RB, Irving PM, Barrett JS, et al,. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 2009; 3: 8-14.
43. McCombie AM, Mulder RT, Gearry RB,. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis 2013; doi:pii: S1873-9946(13)00069-X [Epub ahead of print].